Zimmer Biomet Holdings Inc
NYSE:ZBH
Net Margin
Zimmer Biomet Holdings Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
18.2B USD |
12%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
232.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
186B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.1B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.1B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
112.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.6B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.3B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.7B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
286.9B CNY |
31%
|
Zimmer Biomet Holdings Inc
Glance View
Zimmer Biomet Holdings Inc. stands as a prominent player in the medical device industry, specializing in musculoskeletal healthcare. Emerging from a rich legacy that dates back to its origins in the early 20th century, the company has carved out its niche by innovating in the orthopedic reconstruction sector. Zimmer Biomet operates primarily through designing, manufacturing, and marketing a comprehensive range of orthopedic products, which include joint replacement implants, such as knees, hips, and shoulders, as well as products used for fracture fixation and bone growth stimulation. The innovative edge of Zimmer Biomet lies in its commitment to improving patient outcomes and enhancing the quality of life through advanced surgical and robotic technologies. The company invests significantly in R&D to maintain its competitive edge, constantly pushing the boundaries in personalized solutions and minimally invasive surgery. The company generates revenue by selling its orthopedic and surgical products directly to hospitals, surgical centers, and healthcare providers worldwide. Zimmer Biomet's business model is heavily reliant on the relationships it builds with orthopedic surgeons and healthcare institutions, positioning itself as an essential partner in delivering sophisticated solutions for musculoskeletal health. By focusing on comprehensive, integrated solutions, Zimmer Biomet not only addresses the immediate surgical needs but also engages with the continuum of care in rehabilitation and patient recovery. The company’s strategic acquisitions, sophisticated product pipeline, and global market presence enable it to capture a significant share of the medical device market, ensuring its role as a stalwart in transforming the future of healthcare.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Zimmer Biomet Holdings Inc's most recent financial statements, the company has Net Margin of 11.9%.
You don't have any saved screeners yet